Introduction
Infertile couples that need the help of assisted reproductive technologies in order to achieve a pregnancy embark on a journey that is full of expectations and hopes. Over the last few decades, assisted reproduction treatment has become much safer, more effi cient and more successful. However, even today, situations such as low response and ovarian hyperstimulation cannot be ruled out completely. This is partially due to patientrelated factors and partially due to the fact that different types of drugs used for ovarian stimulation could reveal different degrees of consistency in their bio-potency that result in variable ovarian responses.
An estimated 23−60% of patients drop out of treatment, even though their prognosis may have been evaluated as favourable (Gleicher et al (Gleicher et al (Gleicher ., 1996; Penzias, 2004) . There is currently an ongoing debate as to the most appropriate and relevant outcome measure that defi nes 'success' within the context of assisted reproductive treatment (Bhattacharya and Templeton, 2004; Heijnen et al., 2004; Messinis and Domali, 2004; Wennerholm and Berg, 2004) . Centres that offer assisted reproductive treatment are often assessed according to their published pregnancy rates, but it is well recognized that this simplistic evaluation is inadequate, since it is a fi gure that is readily infl uenced by patient selection criteria, and by accepting high order multiple pregnancies or an excessive incidence of complications such as ovarian hyperstimulation as 'success', instead of failure (Alper et al 'success' , instead of failure (Alper et al 'success' , instead of failure (Alper ., 2002) . Recently, Thurin et al. (2004) reported the results of a large multicentre study in Scandinavia demonstrating that in young patients (<36 years) the transfer of a single fresh embryo, followed by a subsequent frozen embryo if needed, dramatically reduced the multiple birth rate without a substantial reduction in the overall live birth rate. For this approach to be successful, careful patient counselling and the collection of a suffi cient number of high quality oocytes for two single embryo transfer cycles are mandatory.
Birth emphasizing a successful singleton at term (Min et al., 2004) has been suggested as the ideal outcome, but this Article Improving the consistency of ovarian stimulation: follitropin alfa fi lled-by-mass end-point can still be further defi ned within contexts of treatment cycles started, or per patient within a given time period; 'live birth per woman' has also been proposed as an alternative to 'live birth per cycle' (Vail and Gardner, 2003) , but differing time scales make this diffi cult to apply in practice.
The purpose of this review is to address parameters that contribute to the 'quality of assisted reproduction treatment' and to defi ne their impact on treatment decisions.
Defi ning 'quality' in assisted reproduction Alper et al. (2002) have examined factors that should be considered in assessing the overall quality of an IVF centre. They showed that although national registries were initially developed in order to measure 'quality' between centres, their focus on pregnancy rates has instead resulted in pressure to publish high pregnancy rates, sometimes at the cost of high multiple gestation and OHSS rates. International standards in other fi elds usually measure 'quality' in terms of the end product, and the authors suggest that the 'product' for assisted reproduction should be measured in terms of a service -the quality of service that is provided to couples seeking help.
A fundamental goal of quality management is to establish, document and standardize all procedures and protocols, ensuring that they are reproducible and consistent throughout. This quality evaluation should include not only laboratory and clinical aspects (including staff training and development), but also procedures and patient satisfaction (Wikland and Sjoblom, 2000) . Patient satisfaction may be diffi cult to measure; those who take home a healthy baby may be dissatisfi ed with the treatment they received, and, conversely, those who had unsuccessful treatment may feel that their management was satisfactory. This aspect has been evaluated in a number of studies (Halman et al., 1993; Schmidt, 1998; Souter et al., 1998; Hammarberg et al., 2001) , and many clinics ask patients to record their satisfaction at the end of a treatment cycle, as a routine part of quality management. The results of such studies and questionnaires can be used to minimize stress and improve the overall 'quality of life' for patients during treatment. Penzias (2004) suggests that the 'pursuit of excellence should be the goal of every IVF centre', and has outlined a number of strategies that may be used to address patient satisfaction, by implementing simplifi ed, tailored treatments and reduced monitoring to minimize stress and inconvenience. At the same time, the effi ciency and safety of the treatment need to be considered as primary end-points.
Safety of medicines
Ovarian stimulation for multiple follicular development in assisted reproduction is now routinely achieved with the use of gonadotrophins. The history of their therapeutic evolution has recently been reviewed by Lunenfeld (2004) : this review traces the constant quest to reduce the potential risks associated with urinary gonadotrophin preparations, and to improve safety and effi cacy for the patients, leading to the evolution of new pure products manufactured by recombinant technology.
The gonadotrophins used in assisted reproduction were originally prepared from human menopausal urine, and the early crude methods of preparation yielded a product (human menopausal gonadotrophin, HMG) containing only 5% of FSH and LH in a mixture of unidentifi ed urinary proteins (Donini and Montezemolo, 1949; Donini et al., 1964; Lunenfeld and Donini, 1966) . These methods were subsequently refi ned so that products of at least 95% purity (FSH-HP) became available by the early 1990s. When the process of extracting gonadotrophins from urine was started, the menopausal urine was collected in only four centres, located in the Netherlands, Spain, Israel and Italy (Lunenfeld, 2004) . The women participating in these collection centres were known to the centres, and samples could be rejected if there was any indication to do so, such as illness or drug treatment. By the beginning of this millennium, the demand for gonadotrophins had increased 100-fold, and the urine collection process could no longer be reliably traced. Sources had to be extended to many different countries, in Europe, Korea, China, India and South America, so that tracing a donor source became impossible.
Advances in biotechnology during the past 30 years have made it possible to replace urinary-derived products with pure formulations manufactured by recombinant DNA technology. The fi rst recombinant human FSH (r-hFSH; follitropin alfa) preparation for clinical use was produced by Serono Laboratories in 1988, and was licensed for marketing in the European Union as Gonal-f Concerns about the hazards and potential risks of urinary preparations (Shaked et al., 2001; Hill and Collinge, 2003; Seeger et al., 2005) led a number of countries to apply the 'precautionary principle': France, Switzerland and the UK have published warnings regarding the risks associated with urinary products; in 1996, the Australian Drug Evaluation Committee published its resolution on replacement of urinary with recombinant gonadotrophins in view of their higher standard of purity and safety.
Controlling the variables
Assisted reproduction treatment cycles involve a series of different steps, from initial consultation and evaluation, to pituitary down-regulation, ovarian stimulation, monitoring of follicular growth, induction of ovulation, oocyte retrieval, embryo transfer, luteal support, day 15 pregnancy test, and, hopefully, ultrasound assessment of a single viable gestation. Numerous variables are involved at each step, many of which are beyond the control of the patient or the clinical team that manages the treatment. One of the aspects inherent in a total quality management system is to identify variables that can be controlled, and ensure that the different steps during treatment are carried out in a consistent manner. As described below, the development of recombinant DNA technology to produce highly purifi ed hormone preparations, together with refi nements in quality control and production processes (Loumaye et al., 1994; Howles, 1996) , now allows one key variable in the treatment cycle, the consistency of the drug administered, to be better controlled.
FSH is a heterodimer glycoprotein hormone with two noncovalently linked subunits, alpha and beta, glycosylated by post-translational modifi cation (Flack et al., 1994) . In vivo, the native FSH hormone consists of at least 20 different isohormones that differ in their pattern of glycosylation.
During the manufacture of commercial preparations, the source of raw material and the steps involved in the purifi cation process affect the iso-hormone composition of the fi nal product. Commercial preparations consist of a mixture of isoform profi les, and urinary products additionally contain a signifi cant level of contaminating proteins (Guidice et al., 1994 (Guidice et al., , 2001 ; van de Weijer et al van de Weijer et al van de Weijer ., 2003) . Until recently, quantifi cation of the fi nal product relied upon an in-vivo bioassay that measures bioactivity. The in-vivo bioassay for FSH accepted by regulatory agencies is the classic Steelman-Pohley assay (Steelman and Pohley, 1953) , which involves the use of immature female rats. The rats are pre-treated with HCG, and then injected with FSH subcutaneously once daily for 3 days. The ovaries are weighed at autopsy 72 h later, and FSH bioactivity, measured in terms of international units (IU), is estimated based upon ovarian weight gain. This assay has a number of important limitations, the main one being the lack of analytical precision, with a coeffi cient of variation (CV) of 10-20% for each determination. These limitations have been recognized internationally and the US and EU Pharmacopoeias accept a specifi cation range of 80-125% of the potential activity. Thus, ampoules of FSH that have been fi lled on the basis of the bioassay can contain a highly variable amount of the hormone: an ampoule labelled as containing 75 IU FSH could actually have a measured FSH bioactivity between 60 and 94 IU.
The technology used to manufacture recombinant proteins leads to the isolation of a pure rhFSH that can be reliably characterized and quantifi ed by precise physicochemical methods. This molecule has been characterized by a combination of techniques, including sophisticated chromatography and mass spectrometry. The different isoforms of FSH can be separated according to the distribution of their carbohydrate moieties, by glycan mapping (Gervais et al., 2003) , and the number and distribution of sialic acid residues by isoelectric focusing (IEF). These techniques have been extensively validated and are complemented with further physicochemical methods, and are now applied routinely to monitor and control the consistency of the commercial manufacturing process for recombinant gonadotrophins: follitropin alfa, (rhFSH, Gonal-f ® gonadotrophins: follitropin alfa, (rhFSH, Gonal-f ® gonadotrophins: follitropin alfa, (rhFSH, Gonal-f ), Lutropin alfa (rhLH, Luveris ® ), choriogonadotrophin alfa (r-HCG = Ovidrel ® ) and follitropin beta (rhFSH, Puregon ® ). For instance, this is illustrated by an assessment of the follitropin alfa manufacturing history, where an analysis of the results for 309 batches of rhFSH over a 6-year period showed a high degree of consistency between batches (Bassett and Driebergen, 2005) .
The ability to produce a hormone preparation that can be characterized and confi rmed as pure and consistent in specifi c activity means that this product can now be quantifi ed in terms of its mass, in μg protein. The quantity of follitropin alfa in any given sample can be measured by using an optimized biophysical method, size-exclusion high performance liquid chromatography (SE-HPLC). Specifi c activity (ratio of bioactivity to protein content) is expressed in IU/mg protein, and detailed specifi c activity data have been analysed for 100 follitropin alfa rhFSH batches manufactured over a 3-year period, from nine different bioreactor runs. This analysis showed that the specifi c activity of follitropin alfa batches was normally distributed, stable, and that there was no effect of different bioreactor runs. The average specifi c activity of the product was 13,745 IU/mg, and therefore a mass of 5.5 μg is equivalent to 75 IU. These values were subsequently confi rmed on 120 batches (Driebergen and Baer, 2003) and 309 batches (Bassett and Driebergen, 2005) .
There is a general regulatory trend for European regulatory agencies (European Directive 86/609) as well as a commitment of the European Pharmacopoeia Commission to recommend replacing the International Unit as a standard of measurement with mass in micrograms, by using reliable and precise physicochemical analytical methods instead of in-vivo bioassays. Recombinant human growth hormone and recombinant human insulin are now tested by physicochemical methods. As a result of the tightly controlled manufacturing process and sophisticated characterization methodology that ensures the integrity and consistency of each batch of the fi nal product, follitropin alfa can now be fi lled according to mass in μg protein, instead of relying on bioactivity as measured by an imprecise in-vivo bioassay. A recent detailed analysis assessed the manufacturing consistency of the rhFSH follitropin alfa bulk product, determined the consistency and quality of the follitropin alfa fi lled-by-mass (FbM) drug product, and compared the analytical data with follitropin beta. Batches of follitropin alfa FbM, 75 IU, presented as a lyophilized powder in a glass vial for reconstitution with 1 ml of water injection prior to administration was compared with follitropin beta (Puregon ® /Follistim ® ) presented as a solution of rhFSH in a cartridge to be installed in a pen device prior to administration (Basset and Driebergen, 2005) . The data showed high purity and batch-to-batch consistency for follitropin alfa FbM in terms of specifi c activity, protein content, glycan mapping, isoform patterns and purity. The batch-to-batch variability in protein content was lower for follitropin alfa FbM (1.6%) than for follitropin beta (12%), and follitropin beta showed more batchto-batch variability in isoform patterns than follitropin alfa FbM. Concentrations of oxidized alpha subunit were slightly lower for follitropin alfa FbM (1-2.5%) than in follitropin beta (3.5-5.3%). The thorough characterization of Serono's three recombinant gonadotrophins now allows them to be reliably quantifi ed by mass, so that one of the major goals in controlling the variables, the quest for consistency, has been fulfi lled (Keck et al., 2005) .
Clinical benefi ts of follitropin alfa FbM Treatment effi ciency in IVF/ICSI
Since follitropin alfa FbM became available for clinical use in 2002, a number of studies have investigated its effi cacy in IVF/ICSI and ovulation induction treatments, compared with preparations fi lled by bioassay. Hugues et al. (2003) reported a prospective double-blind randomized study where four lots of rhFSH were each divided into one batch of follitropin alfa fi lled by bioassay (FbB) and one batch of follitropin alfa FbM and were compared. Their results showed that patients had a more consistent response to stimulation with the FbM formulation, both within and between centres, in terms of number of oocytes retrieved, as well as a more consistent clinical outcome in terms of pregnancy rate. Balasch et al. (2004) used a study group of women undergoing their fi rst IVF/ICSI cycle, and compared 125 consecutive cycles using follitropin alfa FbB with 125 cycles using the new follitropin alfa FbM formulation. The results of this study showed that treatment with FbM was more effective, in particular with respect to a signifi cantly shorter duration of ovarian stimulation (10.1 versus 11.1 days, P = 0.02) and a trend for higher implantation rate and clinical pregnancy rates (44.0 versus 35.2%, P = 0.1). A multicentre prospective randomized study in 32 assisted reproduction centres in the USA and Latin America comparing the two formulations also reported that the FbM product is safe and effective, delivering a better clinical response, i.e. more oocytes retrieved and higher embryo quality, with a reduction in total FSH administered and number of treatment days (Abuzeid et al., 2001) . Data from these studies are summarized in Table 1 . Similar results have been reported from a large observational study from UK (Lass et al., 2004) .
Treatment effi ciency in ovulation induction

Follitropin alfa
® FbM has also been demonstrated to have an advantage in the treatment of WHO II anovulatory patients for ovulation induction. Data presented by Tredway et al. (2002) and Yeko et al. (2004) (Table 2) showed that the new follitropin alfa FbM formulation allows more precise dosing of FSH, which is critical in anovulatory patients. Improved control of follicular development is refl ected by better precision in choosing the starting dose, and fewer cancelled cycles due to poor response. The number of treatment days and mean dosage required was less for groups of patients treated with FbM than for those treated with FbB, and the results overall confi rm that the use of FbM achieves improved control, fewer treatment days and a lower total dose of administered gonadotrophin compared with FbB.
Multiple pregnancies in controlled ovarian stimulation
Assisted reproduction procedures are associated with an increased multiple pregnancy rate compared with spontaneous versus 15.7 ± versus 18.8 ± 93.6 (NS) (P < 0.0001) ( P < 0.0001) ( P P < 0.02) 41.4 (NS) P < 0.02) 41.4 (NS) P 7.2 11.1 (P = 0.004) ( P = 0.004) ( P P = 0.004) P = 0.004) P NS = not signifi cant. ± 1.8 (P = 0.004) 29.3 ± 11.9 (P < 0.01) 11.9 ± 6.3 versus 10.8 ± n/a 6.8 (P = 0.052) in patients ≤35 years (12.5 versus 10.6) (P < 0. conception (Bertarelli Group, 2003; Gurgan and Demirol, 2004 Sutter ., 2003; Thurin et al., 2004) . However, the situation is slightly different in ovulation induction treatment. Ovulation induction procedures are usually less well documented in registries compared with IVF and ICSI, and exact statistics are not available due to a lack of systematic recording. Available evidence suggests that at least one-third of twin pregnancies and the majority of triplet or higher-order gestations are as a result of ovulation induction procedures (Levene et al., 1992; Norwitz, 1998; Tur et al Norwitz, 1998; Tur et al Norwitz, 1998; Tur ., 2001) . The risk of multiple gestation in ovulation induction can be dealt with by reducing the number of follicles under ultrasound guidance, or by carrying out an IVF procedure instead. The use of tailored treatment protocols that are based upon using an FbM rhFSH that yields reliably a consistent ovarian response is a logical approach to controlling the risk of multiple gestation after ovulation induction.
Reduced incidence of cancelled cycles and OHSS
Cancelled cycles due to inadequate or excessive ovarian response represent a major source of disappointment for the couple treated, even more in countries where treatment costs are not reimbursed. Reducing the incidence of cancelled cycles is a major concern in assisted reproduction, and signifi cant benefi t can be gained in this respect by using a drug that can be relied upon as consistently effective. In a similar manner, patients who have shown an excessive response to stimulation in a previous cycle can be more carefully managed with the accurate dosing that FbM preparations allow.
Conclusions
Over the last few decades, major improvements in assisted reproduction procedures have been achieved. This does not only refer to the technical aspects of the treatment but even more to the drugs used for ovarian stimulation: in the beginning of assisted reproduction treatments urine-derived gonadotrophins were used for ovarian stimulation. These preparations were associated with low purity, low specifi c activity and a lack of traceability. Recombinant gonadotrophins have come into the market in the early 1990s and their higher purity and consistency have resulted in higher treatment effi ciency compared with urine-derived gonadotrophins in terms of pregnancy rates and total dose of gonadotrophin per live birth (Ludwig et al., 2004) . The latest achievement in ovarian stimulation treatment was the development of gonadotrophins FbM.
The use of these refi ned and tested products allows a safer and more streamlined approach to assisted reproduction cycle management, with tailored patient-friendly protocols and reduced monitoring based upon confi dence in a consistent response to stimulation. This superior control can minimize the risks of cancelled cycles, OHSS and multiple births after assisted reproduction as well as after ovulation induction therapy.
"Quality is never an accident; it is always the result of high intention, sincere effort, intelligent direction and skilful execution; it represents the wise choice of many alternatives." William A Foster.
